- Home
- NET vs ALNY Comparison
NET vs ALNY Comparison
Compare NET & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NET
- ALNY
- Stock Information
- Founded
- NET 2009
- ALNY 2002
- Country
- NET United States
- ALNY United States
- Employees
- NET N/A
- ALNY N/A
- Industry
- NET Computer Software: Prepackaged Software
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- NET Technology
- ALNY Health Care
- Exchange
- NET Nasdaq
- ALNY Nasdaq
- Market Cap
- NET 39.6B
- ALNY 33.1B
- IPO Year
- NET 2019
- ALNY 2004
- Fundamental
- Price
- NET $112.64
- ALNY $245.44
- Analyst Decision
- NET Hold
- ALNY Buy
- Analyst Count
- NET 26
- ALNY 23
- Target Price
- NET $98.72
- ALNY $298.59
- AVG Volume (30 Days)
- NET 2.9M
- ALNY 671.5K
- Earning Date
- NET 02-06-2025
- ALNY 02-13-2025
- Dividend Yield
- NET N/A
- ALNY N/A
- EPS Growth
- NET N/A
- ALNY N/A
- EPS
- NET N/A
- ALNY N/A
- Revenue
- NET $1,572,153,000.00
- ALNY $2,094,795,000.00
- Revenue This Year
- NET $29.40
- ALNY $25.14
- Revenue Next Year
- NET $25.74
- ALNY $17.35
- P/E Ratio
- NET N/A
- ALNY N/A
- Revenue Growth
- NET 30.04
- ALNY 21.54
- 52 Week Low
- NET $66.24
- ALNY $141.98
- 52 Week High
- NET $119.42
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- NET 59.68
- ALNY 43.56
- Support Level
- NET $107.00
- ALNY $233.41
- Resistance Level
- NET $119.42
- ALNY $249.58
- Average True Range (ATR)
- NET 4.17
- ALNY 7.63
- MACD
- NET -0.64
- ALNY -0.21
- Stochastic Oscillator
- NET 58.17
- ALNY 48.68
About NET Cloudflare Inc.
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.